Immunomodulators: interleukins, interferons, and IV immunoglobulin

  • Joris J. Roelofs
  • Daniel Abramowicz
  • Sandrine Florquin

The outstanding progress in immunology and the development of new technologies have resulted in the introduction of new immunotherapies, the so-called “immunomodulators”, for autoimmune diseases, inflammatory disorders, allograft rejection, and cancer. These immunomodulators comprise recombinant cytokines and specific blocking or depleting antibodies. Many of these therapies achieve their effect by stimulating the release of cytokines. The term cytokines includes interleukins (IL-), chemokines, growth factors, interferons (IFN), colony stimulating factors (CSF), and tumor necrosis factors (TNF). These molecules are involved in inflammation, cell proliferation and apoptosis, tissue injury and repair.

These new therapeutic tools can be associated with side effects among which nephrotoxicity. The most common immunomodulators associated with nephrotoxicity are described in Table 1. The nephrotoxic side effects of immunomodulators can be roughly divided into (ischemic) tubular necrosis, thrombotic microangiopathy, serum sickness, and autoimmune disorders.


Nephrotic Syndrome Acute Renal Failure Systemic Inflammatory Response Syndrome Hemolytic Uremic Syndrome Mycosis Fungoides 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia, J Clin Invest 1992, 90:693-698PubMedGoogle Scholar
  2. 2.
    Ramesh G, Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity, J Clin Invest 2002, 110:835-842PubMedGoogle Scholar
  3. 3.
    Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, Akira S, van der Poll T, Weening JJ, Florquin S: Renalassociated TLR2 mediates ischemia/reperfusion injury in the kidney, J Clin Invest 2005, 115:2894-2903PubMedGoogle Scholar
  4. 4.
    Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G: Tumor necrosis factor induces glomerular damage in the rabbit, Am J Pathol 1989, 134:419-430PubMedGoogle Scholar
  5. 5.
    Wang J, Dunn MJ: Platelet-activating factor mediates endotoxin-induced acute renal insufficiency in rats, Am J Physiol 1987, 253: F1283-1289PubMedGoogle Scholar
  6. 6.
    von Pirquet C, Schick B: Das Serumkrankheit. Edited by Leipzig, Deuticke, 1905, pGoogle Scholar
  7. 7.
    Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A: Drug-induced lupus erythematosus, Autoimmunity 2005, 38:507-518PubMedGoogle Scholar
  8. 8.
    Vielhauer V, Mayadas TN: Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation, Semin Nephrol 2007, 27:286-308PubMedGoogle Scholar
  9. 9.
    Belldegrun A, Webb DE, Austin HA, 3rd, Steinberg SM, White DE, Linehan WM, Rosenberg SA: Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer, Ann Intern Med 1987, 106:817-822PubMedGoogle Scholar
  10. 10.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or highdose interleukin-2 alone, N Engl J Med 1987, 316:889-897PubMedGoogle Scholar
  11. 11.
    Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA: Clinical effects and toxicity of interleukin-2 in patients with cancer, Cancer 1986, 58:2764-2772PubMedGoogle Scholar
  12. 12.
    Marroquin CE, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ: Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer, J Immunother (1997) 2000, 23:387-392Google Scholar
  13. 13.
    Kozeny GA, Nicolas JD, Creekmore S, Sticklin L, Hano JE, Fisher RI: Effects of interleukin-2 immunotherapy on renal function, J Clin Oncol 1988, 6:1170-1176PubMedGoogle Scholar
  14. 14.
    Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH: Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion, J Clin Oncol 1990, 8:1839-1846PubMedGoogle Scholar
  15. 15.
    Vlasveld LT, van de Wiel-van Kemenade E, de Boer AJ, Sein JJ, Gallee MP, Krediet RT, Mellief CJ, Rankin EM, Hekman A, Figdor CG: Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer, Cancer Immunol Immunother 1993, 36:210-213PubMedGoogle Scholar
  16. 16.
    Textor SC, Margolin K, Blayney D, Carlson J, Doroshow J: Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man, Am J Med 1987, 83:1055-1061PubMedGoogle Scholar
  17. 17.
    Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins M: Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study, Cancer J Sci Am 1997, 3:157-162PubMedGoogle Scholar
  18. 18.
    Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie, N Engl J Med 1998, 338:1272-1278Google Scholar
  19. 19.
    Schomburg A, Kirchner H, Atzpodien J: Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy, J Cancer Res Clin Oncol 1993, 119:745-755PubMedGoogle Scholar
  20. 20.
    Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, et al.: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines, J Clin Oncol 1989, 7:486-498PubMedGoogle Scholar
  21. 21.
    Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2, J Immunol 1986, 137:1735-1742PubMedGoogle Scholar
  22. 22.
    Ponce P, Cruz J, Travassos J, Moreira P, Oliveira J, Melo-Gomes E, Gouveia J: Renal toxicity mediated by continuous infusion of recombinant interleukin-2, Nephron 1993, 64:114-118PubMedGoogle Scholar
  23. 23.
    Memoli B, De Nicola L, Libetta C, Scialo A, Pacchiano G, Romano P, Palmieri G, Morabito A, Lauria R, Conte G, et al.: Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion, Am J Kidney Dis 1995, 26:27-33PubMedGoogle Scholar
  24. 24.
    Palmieri G, Morabito A, Lauria R, Montesarchio V, Matano E, Memoli B, Libetta C, Rea A, Merola C, Correale P, et al.: Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function, Eur J Cancer 1993, 29A:1119-1122PubMedGoogle Scholar
  25. 25.
    Rafi-Janajreh AQ, Chen D, Schmits R, Mak TW, Grayson RL, Sponenberg DP, Nagarkatti M, Nagarkatti PS: Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2, J Immunol 1999, 163:1619-1627PubMedGoogle Scholar
  26. 26.
    Hall TJ, James PR, Cambridge G: Interleukin-2 nephrotoxicity assessed in vitro, Res Commun Chem Pathol Pharmacol 1991, 73:375-378PubMedGoogle Scholar
  27. 27.
    Phillips TM: Interferon-alpha induces renal dysfunction and injury, Curr Opin Nephrol Hypertens 1996, 5:380-383PubMedGoogle Scholar
  28. 28.
    Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z: Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients, Ann Intern Med 1982, 96:549-556PubMedGoogle Scholar
  29. 29.
    Abdulhay G, DiSaia PJ, Blessing JA, Creasman WT: Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study, Am J Obstet Gynecol 1985, 152:418-423PubMedGoogle Scholar
  30. 30.
    Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger C, Maluish AE, Oldham RK: A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients, Jama 1982, 248:2461-2466PubMedGoogle Scholar
  31. 31.
    Quesada JR, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman JU: Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma, Am J Med 1984, 77:427-432PubMedGoogle Scholar
  32. 32.
    Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU: Clinical toxicity of interferons in cancer patients: a review, J Clin Oncol 1986, 4:234-243PubMedGoogle Scholar
  33. 33.
    Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Vanacore R, Liberati AM, Gerli R, Greco F, Moretti A, et al.: Interferonalpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial, Blood 1993, 81:1132-1136PubMedGoogle Scholar
  34. 34.
    Dimitrov Y, Heibel F, Marcellin L, Chantrel F, Moulin B, Hannedouche T: Acute renal failure and nephrotic syndrome with alpha interferon therapy, Nephrol Dial Transplant 1997, 12:200-203PubMedGoogle Scholar
  35. 35.
    Dhib M, Bakhache E, Postec E, Vanrenterghem B, Le Roy F, Azar R, Francois A, Boldron A, Amaria R, Ozenne G, Hermelin A: [Nephrotic syndrome complicating treatment with interferon alpha], Presse Med 1996, 25:1066-1068PubMedGoogle Scholar
  36. 36.
    Gresser I, Maury C, Tovey M, Morel-Maroger L, Pontillon F: Progressive glomerulonephritis in mice treated with interferon preparations at birth, Nature 1976, 263:420-422PubMedGoogle Scholar
  37. 37.
    Morel-Maroger L, Sloper JC, Vinter J, Woodrow D, Gresser I: An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period, Lab Invest 1978, 39:513-522PubMedGoogle Scholar
  38. 38.
    Lederer E, Truong L: Unusual glomerular lesion in a patient receiving long-term interferon alpha, Am J Kidney Dis 1992, 20:516-518PubMedGoogle Scholar
  39. 39.
    Parker MG, Atkins MB, Ucci AA, Levey AS: Rapidly progressive glomerulonephritis after immunotherapy for cancer, J Am Soc Nephrol 1995, 5:1740-1744PubMedGoogle Scholar
  40. 40.
    Selby P, Kohn J, Raymond J, Judson I, McElwain T: Nephrotic syndrome during treatment with interferon, Br Med J (Clin Res Ed) 1985, 290:1180Google Scholar
  41. 41.
    Herrman J, Gabriel F: Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon, N Engl J Med 1987, 316:112-113PubMedGoogle Scholar
  42. 42.
    Colovic M, Jurisic V, Jankovic G, Jovanovic D, Nikolic LJ, Dimitrijevic J: Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature, J Clin Pathol 2006, 59:879-881PubMedGoogle Scholar
  43. 43.
    Averbuch SD, Austin HA, 3rd, Sherwin SA, Antonovych T, Bunn PA, Jr., Longo DL: Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides, N Engl J Med 1984, 310:32-35PubMedCrossRefGoogle Scholar
  44. 44.
    Traynor A, Kuzel T, Samuelson E, Kanwar Y: Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma, Nephron 1994, 67:94-100PubMedGoogle Scholar
  45. 45.
    Rettmar K, Kienast J, van de Loo J: Minimal change glomerulonephritis with reversible proteinuria during interferon alpha 2a therapy for chronic myeloid leukemia, Am J Hematol 1995, 49:355-356PubMedGoogle Scholar
  46. 46.
    Shah M, Jenis EH, Mookerjee BK, Schriber JR, Baer MR, Herzig GP, Wetzler M: Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy, Cancer 1998, 83:1938-1946PubMedGoogle Scholar
  47. 47.
    Roeloffzen WW, Hospers GA, De Vries EG, Navis GJ: Renal failure after treatment with interferon alpha 2b, Anticancer Res 2002, 22:1929-1931PubMedGoogle Scholar
  48. 48.
    Laboudi A, Makdassi R, Choukroun G, Fournier A: [Acute renal insufficiency secondary to interferon], Nephrologie 2003, 24:181-185PubMedGoogle Scholar
  49. 49.
    Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM: Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?, Cancer 1999, 85:2583-2588PubMedGoogle Scholar
  50. 50.
    Harvey M, Rosenfeld D, Davies D, Hall BM: Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence?, Am J Hematol 1994, 46:152-153PubMedGoogle Scholar
  51. 51.
    Coroneos E, Petrusevska G, Varghese F, Truong LD: Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy, Am J Kidney Dis 1996, 28:888-892PubMedGoogle Scholar
  52. 52.
    Bellaiche G, Guettier C, Duboust A, Ley G, Slama JL: [Nephrotic syndrome with acute renal failure due to focal segmental glomerulosclerosis in a patient treated with alpha-interferon for chronic hepatitis C], Gastroenterol Clin Biol 2000, 24:465PubMedGoogle Scholar
  53. 53.
    Gordon AC, Edgar JD, Finch RG: Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia, J Infect 1998, 36:229-230PubMedGoogle Scholar
  54. 54.
    Ohta S, Yokoyama H, Wada T, Sakai N, Shimizu M, Kato T, Furuichi K, Segawa C, Hisada Y, Kobayashi K: Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy, Am J Kidney Dis 1999, 33:1040-1048PubMedGoogle Scholar
  55. 55.
    Yamabe H, Johnson RJ, Gretch DR, Osawa H, Inuma H, Sasaki T, Kaizuka M, Tamura N, Tsunoda S, Fujita Y, et al.: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha, Am J Kidney Dis 1995, 25:67-69PubMedGoogle Scholar
  56. 56.
    Sarac E, Bastacky S, Johnson JP: Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection, Am J Kidney Dis 1997, 30:113-115PubMedGoogle Scholar
  57. 57.
    Johnson RJ, Gretch DR, Couser WG, Alpers CE, Wilson J, Chung M, Hart J, Willson R: Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy, Kidney Int 1994, 46:1700-1704Google Scholar
  58. 58.
    Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D, Suc JM: Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients, Nephrol Dial Transplant 1995, 10 Suppl 6:93-96PubMedGoogle Scholar
  59. 59.
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D: Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C, Nephron 1996, 74:512-516PubMedGoogle Scholar
  60. 60.
    Gordon A, Menahem S, Mitchell J, Jenkins P, Dowling J, Roberts SK: Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy, Nephrol Dial Transplant 2004, 19:2155Google Scholar
  61. 61.
    Batisse D, Karmochkine M, Jacquot C, Kazatchkine MD, Weiss L: Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa, Eur J Gastroenterol Hepatol 2004, 16:701-703PubMedGoogle Scholar
  62. 62.
    Schiller JH, Storer B, Willson JK, Borden EC: Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy, Cancer Treat Rep 1987, 71:945-952PubMedGoogle Scholar
  63. 63.
    Schiller JH, Storer B, Witt PL, Nelson B, Brown RR, Horisberger M, Grossberg S, Borden EC: Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion, Cancer Res 1990, 50:4588-4594PubMedGoogle Scholar
  64. 64.
    Thompson JA, Cox WW, Lindgren CG, Collins C, Neraas KA, Bonnem EM, Fefer A: Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects, Cancer Immunol Immunother 1987, 25:47-53PubMedGoogle Scholar
  65. 65.
    Takei Y, Sims TN, Urmson J, Halloran PF: Central role for interferon-gamma receptor in the regulation of renal MHC expression, J Am Soc Nephrol 2000, 11:250-261PubMedGoogle Scholar
  66. 66.
    Sriskandan K, Garner P, Watkinson J, Pettingale KW, Brinkley D, Calman FM, Tee DE: A toxicity study of recombinant interferongamma given by intravenous infusion to patients with advanced cancer, Cancer Chemother Pharmacol 1986, 18:63-68PubMedGoogle Scholar
  67. 67.
    Ault BH, Stapleton FB, Gaber L, Martin A, Roy S, 3rd, Murphy SB: Acute renal failure during therapy with recombinant human gamma interferon, N Engl J Med 1988, 319:1397-1400PubMedCrossRefGoogle Scholar
  68. 68.
    Green MC, Murray JL, Hortobagyi GN: Monoclonal antibody therapy for solid tumors, Cancer Treat Rev 2000, 26:269-286PubMedGoogle Scholar
  69. 69.
    Goldstein G: Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation, Transplant Proc 1987, 19:1-6PubMedGoogle Scholar
  70. 70.
    Van Wauwe JP, De Mey JR, Goossens JG: OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties, J Immunol 1980, 124:2708-2713PubMedGoogle Scholar
  71. 71.
    Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, Wybran J, Kinnaert P, Dupont E, Toussaint C: Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients, Transplantation 1989, 47:606-608PubMedGoogle Scholar
  72. 72.
    Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach JF: Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected], N Engl J Med 1989, 320:1420-1421PubMedCrossRefGoogle Scholar
  73. 73.
    Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF: In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids, Transplantation 1990, 49:697702Google Scholar
  74. 74.
    Bloemena E, ten Berge IJ, Surachno J, Wilmink JM: Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients, Transplantation 1990, 50:330-331PubMedGoogle Scholar
  75. 75.
    Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, Laskow DA, Diethelm AG, Curtis JJ: OKT3 first-dose reaction: association with T cell subsets and cytokine release, Kidney Int 1991, 39:141-148PubMedGoogle Scholar
  76. 76.
    Toussaint C, De Pauw L, Vereerstraeten P, Kinnaert P, Abramowics D, Goldman M: Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation, Transplantation 1989, 48:524-526PubMedGoogle Scholar
  77. 77.
    Batiuk TD, Bennett WM, Norman DJ: Cytokine nephropathy during antilymphocyte therapy, Transplant Proc 1993, 25:27-30PubMedGoogle Scholar
  78. 78.
    Abramowicz D, Pradier O, Marchant A, Florquin S, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Goldman M: Induction of thromboses within renal grafts by high-dose prophylactic OKT3, Lancet 1992, 339:777-778PubMedGoogle Scholar
  79. 79.
    Abramowicz D, Pradier O, De Pauw L, Kinnaert P, Mat O, Surquin M, Doutrelepont JM, Vanherweghem JL, Capel P, Vereerstraeten P, et al.: High-dose glucocorticosteroids increase the procoagulant effects of OKT3, Kidney Int 1994, 46:1596-1602PubMedGoogle Scholar
  80. 80.
    Gomez E, Aguado S, Gago E, Escalada P, Alvarez-Grande J: Main graft vessels thromboses due to conventional-dose OKT3 in renal transplantation, Lancet 1992, 339:1612-1613PubMedGoogle Scholar
  81. 81.
    Noel C, Hazzan M, Coppin MC, Pruvot FR, Bridoux F, Lelievre G: Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3), Transplant Proc 1995, 27:2438-2439PubMedGoogle Scholar
  82. 82.
    Shankar R, Bastani B, Salinas-Madrigal L, Sudarshan B: Acute thrombosis of the renal transplant artery after a single dose of OKT3, Am J Nephrol 2001, 21:141-144PubMedGoogle Scholar
  83. 83.
    Isaacs JD, Burrows N, Wing M, Keogan MT, Rebello PR, Watts RA, Pye RJ, Norris P, Hazelman BL, Hale G, Waldmann H: Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease, Clin Exp Immunol 1997, 110:158-166PubMedCrossRefGoogle Scholar
  84. 84.
    Gopal AK, Press OW: Clinical applications of anti-CD20 antibodies, J Lab Clin Med 1999, 134:445-450PubMedGoogle Scholar
  85. 85.
    Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients, Eur J Haematol 1999, 62:76-82PubMedCrossRefGoogle Scholar
  86. 86.
    Finger E, Scheinberg M: Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia, J Clin Rheumatol 2007, 13:94-95PubMedGoogle Scholar
  87. 87.
    Todd DJ, Helfgott SM: Serum sickness following treatment with rituximab, J Rheumatol 2007, 34:430-433PubMedGoogle Scholar
  88. 88.
    Schutgens RE: Rituximab-induced serum sickness, Br J Haematol 2006, 135:147PubMedGoogle Scholar
  89. 89.
    Ramamoorthy SK, Marangolo M, Durrant E, Akima S, Gottlieb DJ: Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis, Leuk Lymphoma 2006, 47:747-750PubMedGoogle Scholar
  90. 90.
    Van Deventer SJ: Immunotherapy of Crohn’s disease, Scand J Immunol 2000, 51:18-22PubMedGoogle Scholar
  91. 91.
    Nancey S, Blanvillain E, Parmentier B, Flourie B, Bayet C, Bienvenu J, Fabien N: Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn’s disease, Inflamm Bowel Dis 2005, 11:986-991PubMedGoogle Scholar
  92. 92.
    Saint Marcoux B, De Bandt M: Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France, Joint Bone Spine 2006, 73:710-713PubMedGoogle Scholar
  93. 93.
    Chin G, Luxton G, Harvey JM: Infliximab and nephrotic syndrome, Nephrol Dial Transplant 2005, 20:2824-2826PubMedGoogle Scholar
  94. 94.
    Schiff MH, Whelton A: Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis, Semin Arthritis Rheum 2000, 30:196-208PubMedGoogle Scholar
  95. 95.
    Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G: Henoch-Schonlein purpura after etanercept therapy for psoriasis, J Clin Rheumatol 2006, 12:249-251PubMedGoogle Scholar
  96. 96.
    Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D’Agati VD: Development of glomeru- lonephritis during anti-TNF-alpha therapy for rheumatoid arthritis, Nephrol Dial Transplant 2005, 20:1400-1406PubMedGoogle Scholar
  97. 97.
    Berard JL, Velez RL, Freeman RB, Tsunoda SM: A review of interleukin-2 receptor antagonists in solid organ transplantation, Pharmacotherapy 1999, 19:1127-1137PubMedGoogle Scholar
  98. 98.
    Bonatti H, Brandacher G, Boesmueller C, Cont M, Hengster P, Rosenkranz AR, Krugmann J, Margreiter R: Hemolytic uremic syn- drome following Campath-1H induction, Transpl Int 2007, 20:386-389PubMedGoogle Scholar
  99. 99.
    Osborne WL, Lennard AL: Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine, Haematologica 2005, 90:ECR05PubMedGoogle Scholar
  100. 100.
    Pascual J, Mezrich JD, Djamali A, Leverson G, Chin LT, Torrealba J, Bloom D, Voss B, Becker BN, Knechtle SJ, Sollinger HW, Pirsch JD, Samaniego MD: Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation, Transplantation 2007, 83:1429-1434PubMedGoogle Scholar
  101. 101.
    Hill P, Gagliardini E, Ruggenenti P, Remuzzi G: Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy, Nephrol Dial Transplant 2005, 20:1741-1744PubMedGoogle Scholar
  102. 102.
    Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity, Qjm 2000, 93:433-439PubMedGoogle Scholar
  103. 103.
    Gupta N, Ahmed I, Nissel-Horowitz S, Patel D, Mehrotra B: Intravenous gammglobulin-associated acute renal failure, Am J Hematol 2001, 66:151-152PubMedGoogle Scholar
  104. 104.
    Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ: Acute renal failure associated with immunoglobulin therapy, Am J Kidney Dis 1995, 25:228-234PubMedGoogle Scholar
  105. 105.
    Orbach H, Tishler M, Shoenfeld Y: Intravenous immunoglobulin and the kidney--a two-edged sword, Semin Arthritis Rheum 2004, 34:593-601PubMedGoogle Scholar
  106. 106.
    Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR: Acute renal failure resulting from intravenous immunoglobulin therapy, Arch Neurol 1993, 50:137-139PubMedGoogle Scholar
  107. 107.
    Kobosko J, Nicol P: Renal toxicity of intravenous immunoglobulin, Clin Nephrol 1992, 37:216-217PubMedGoogle Scholar
  108. 108.
    Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ: Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin, Am J Med 1987, 82:624-629PubMedGoogle Scholar
  109. 109.
    Walton GD, Gualtieri RJ: Antithymocyte globulin-induced adult respiratory distress syndrome, Arch Intern Med 1998, 158:1380PubMedGoogle Scholar
  110. 110.
    Busani S, Rinaldi L, Begliomini B, Pasetto A, Girardis M: Thymoglobulin-induced severe cardiovascular reaction and acute renal failure in a patient scheduled for orthotopic liver transplantation, Minerva Anestesiol 2006, 72:243-248PubMedGoogle Scholar
  111. 111.
    Levine JM, Lien YH: Antithymocyte globulin-induced acute renal failure, Am J Kidney Dis 1999, 34:1155PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Joris J. Roelofs
    • 1
  • Daniel Abramowicz
    • 2
  • Sandrine Florquin
    • 1
  1. 1.Department of PathologyAcademic Medical Center, University of AmsterdamAmsterdamThe Netherlands
  2. 2.Nephrology DepartmentErasme HospitalBrusselsBelgium

Personalised recommendations